Suchergebnisse

Within the EU, there exist deliberate attempts at the introduction of passenger-friendly integrated public passenger transport (PPT), which should solve many inconveniences that now hamper passengers in using the existing transportation system and should increase the PPT demand. The centerpiece of the integrated PPT system is the integrated ticket, which ideally also implies the integrated pricing (tariff) system. Due to the decline in PPT services in Slovenia, the responsible Ministry launched a project aimed at the development of integrated PPT. A study was conducted as part of the project, focusing on the ticket pricing (tariff) model in relation to the existing customer structure. The model is largely based on the transport policy principle, rather than the cost principle, with the Austrian state of Styria as the selected comparable region. This article also presents the introduction of very reasonably priced integrated monthly student ticket in Slovenia, which demonstrated the importance of substantial government subsidies leading to an increase in student ridership. Adapted from the source document.

Inter-firm relations vary significantly between capitalist economies as a result of institutional differences, especially in terms of trust and mechanisms ensuring adherence to contractual commitments. The transformation of the state socialist economies in Eastern Europe might be expected to destroy the pre-1989 relationships between suppliers and customers and generate new types of connections. This study of 18 Hungarian firms and eight Slovenian firms found significant differences between the ways companies transformed and/or preserved the way they managed their supplier-customer relationships. These differences were mainly due to the differences between the legacies of state socialism, the mode of the macroeconomic transformation and the general business environment in the two countries. This study also shows that unlike the Japanese firms studied by Sako, firms in Eastern Europe show contradictory behaviours if Sako's indicators of trust are applied.

Germline mutations in CDKN2A are frequently identified among melanoma kindreds and are associated with increased atypical nevus counts. However, a clear relationship between pathogenic CDKN2A mutation carriage and other nevus phenotypes including counts of common acquired nevi has not yet been established. Using data from GenoMEL, we investigated the relationships between CDKN2A mutation carriage and 2-mm, 5-mm, and atypical nevus counts among blood-related members of melanoma families. Compared with individuals without a pathogenic mutation, those who carried one had an overall higher prevalence of atypical (odds ratio = 1.64; 95% confidence interval = 1.18-2.28) nevi but not 2-mm nevi (odds ratio = 1.06; 95% confidence interval = 0.92-1.21) or 5-mm nevi (odds ratio = 1.26; 95% confidence interval = 0.94-1.70). Stratification by case status showed more pronounced positive associations among non-case family members, who were nearly three times (odds ratio = 2.91; 95% confidence interval = 1.75-4.82) as likely to exhibit nevus counts at or above the median in all three nevus categories simultaneously when harboring a pathogenic mutation (vs. not harboring one). Our results support the hypothesis that unidentified nevogenic genes are co-inherited with CDKN2A and may influence carcinogenesis. ; European Commission under the 6th and 7th Framework Programme ; Cancer Research UK Programme ; Cancer Research UK ; US National Institutes of Health ; NIH, National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics ; National Health and Medical Research Council of Australia ; Cancer Council New South Wales ; Cancer Institute New South Wales ; Cancer Council Victoria ; Cancer Council Queensland ; CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) ; FAPESP (Fundacao para o Amparo da Pesquisa do Estado de Sao Paulo)-SP, Brazil ; National Health and Medical Research Council of Australia ; NCI ; Cancer Research Foundations of Radiumhemmet ; Swedish Cancer Society ; Paulsson Trust ; Lund University ; European Research Council ; Fondo de Investigaciones Sanitarias, Spain ; CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain ; Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, Una manera de hacer Europa ; Catalan Government, Spain ; Fundacio La Marato de TV3, Catalonia, Spain ; Italian Association for Cancer research (AIRC) ; Italian Ministry of Health ; Programme Hospitalier de Recherche Clinique ; Institut National du Cancer (INCA) ; Comision Honoraria de Lucha Contra el Cancer, Montevideo, Uruguay ; Dutch Cancer Society ; CONACYT, Mexico ; NHMRC ; Cancer Institute NSW ; National Institutes of Health ; Texas A&M Hlth Sci Ctr, Dept Epidemiol & Biostat, College Stn, TX USA ; Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA USA ; Natl Canc Inst, Div Canc Epidemiol & Genet, Human Genet Program, Bethesda, MD USA ; Hop Cochin, AP HP, Paris, France ; Univ Paris 05, Paris, France ; Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Dept Dermatol, Tel Aviv, Israel ; Leiden Univ, Med Ctr, Dept Dermatol, Leiden, Netherlands ; St James Univ Hosp, Canc Res UK Clin Ctr Leeds, Leeds Inst Canc & Pathol, Sect Epidemiol & Biostat, Leeds, W Yorkshire, England ; Univ Paris Saclay, Gustave Roussy, Dept Biol & Pathol Med, INSERM,U1186, Villejuif, France ; Univ Genoa, Dept Internal Med & Med Specialties, Genoa, Italy ; IRCCS, AOU San Martino IST, Genoa, Italy ; Maurizio Bufalini Hosp, Dermatol Unit, Cesena, Italy ; Univ Utah, Dept Genet Epidemiol, Salt Lake City, UT USA ; Univ Utah, Dept Biomed Informat, Salt Lake City, UT USA ; Hosp Clin Barcelona, IDIBAPS, Dermatol Dept, Melanoma Unit, Barcelona, Spain ; CIBER Enfermedades Raras, Barcelona, Spain ; Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia ; Melanoma Inst Australia, Westmead, NSW, Australia ; Univ Paris Diderot, Univ Sorbonne Paris Cite, INSERM, Genet Variat & Human Dis Unit,UMR 946, Paris, France ; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA USA ; Univ Copenhagen Hosp, Dept Clin Genet, Copenhagen, Denmark ; Univ Fed Ciencias Sau Porto Alegre, Porto Alegre, RS, Brazil ; Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden ; QIMR Berghofer Med Res Inst, Herston, Qld, Australia ; Inst Oncol Ljubljana, Ljubljana, Slovenia ; Lund Univ, Dept Clin Sci, Lund, Sweden ; Lund Univ, Dept Surg, Lund, Sweden ; Univ Fed Sao Paulo, Escola Paulista Med, Dept Pathol, Sao Paulo, Brazil ; Univ Republica, Hosp Clin, Unidad Lesiones Pigmentadas Catedra Dermatol, Montevideo, Uruguay ; Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA ; Univ Sydney, Westmead Millennium Inst, Westmead Inst Canc Res, Sydney, NSW, Australia ; Inst Valenciano Oncol, Dept Dermatol, Valencia, Spain ; Latvian Biomed Res & Study Ctr, Riga, Latvia ; H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA ; Univ Fed Sao Paulo, Escola Paulista Med, Dept Pathol, Sao Paulo, Brazil ; European Commission under the 6th and 7th Framework Programme: LSH-CT-2006-018702 ; Cancer Research UK Programme: C588/A4994 ; Cancer Research UK Programme: C588/ A10589 ; Cancer Research UK: C8216/A6129 ; US National Institutes of Health: R01-CA83115 ; US National Institutes of Health: R01CA5558-01A2 ; US National Institutes of Health: 5R25-CA147832-04 ; National Health and Medical Research Council of Australia: NHMRC 107359 ; National Health and Medical Research Council of Australia: 402761 ; National Health and Medical Research Council of Australia: 633004 ; National Health and Medical Research Council of Australia: 566946 ; National Health and Medical Research Council of Australia: 211172 ; Cancer Council New South Wales: 77/00 ; Cancer Council New South Wales: 06/10 ; Cancer Institute New South Wales: CINSW 05/TPG/1-01 ; |Cancer Institute New South Wales: 10/TPG/1-02 ; Cancer Council Queensland: 371 ; FAPESP: 2007/04313-2 ; NCI: CA88363 ; European Research Council: ERC-2011-294576 ; Fondo de Investigaciones Sanitarias, Spain: P.I. 09/01393 ; Fondo de Investigaciones Sanitarias, Spain: P.I. 12/ 00840 ; Catalan Government, Spain: AGAUR 2009 SGR 1337 ; Catalan Government, Spain: AGAUR 2014_SGR_603 ; Fundacio La Marato de TV3, Catalonia, Spain: 201331-30 ; Italian Association for Cancer research (AIRC): 15460 ; Programme Hospitalier de Recherche Clinique: PHRC-AOM-07-195 ; Dutch Cancer Society: UL 2012-5489 ; CONACYT, Mexico: 152256/158706 ; NHMRC: 1063593 ; Cancer Institute NSW: 15/CDF/1-14 ; National Institutes of Health: P30CA042014 ; Web of Science